Sanctuary Advisors LLC Increases Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sanctuary Advisors LLC increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,193 shares of the specialty pharmaceutical company’s stock after buying an additional 1,439 shares during the period. Sanctuary Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,650,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Pacer Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after acquiring an additional 115,102 shares in the last quarter. Franklin Resources Inc. grew its stake in Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares during the period. Thompson Siegel & Walmsley LLC raised its holdings in Jazz Pharmaceuticals by 8.3% in the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock worth $87,035,000 after purchasing an additional 59,685 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Jazz Pharmaceuticals by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after buying an additional 42,587 shares during the period. Finally, Systematic Financial Management LP boosted its holdings in shares of Jazz Pharmaceuticals by 11.7% during the 3rd quarter. Systematic Financial Management LP now owns 283,977 shares of the specialty pharmaceutical company’s stock valued at $31,638,000 after buying an additional 29,647 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $136.69 on Tuesday. The company has a 50 day simple moving average of $125.08 and a two-hundred day simple moving average of $118.24. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $8.26 billion, a P/E ratio of 19.25, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $138.27.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 5,053 shares of company stock valued at $617,442. Company insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research reports. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, TD Cowen lowered their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.